Targeted Therapy in the Treatment of Breast Cancer

Saturday, May 17, 2008 • Dinner Program 6 PM – 8 PM Philadelphia Marriott Downtown • Grand Ballroom, Salons C, D, & E Philadelphia, PA RSVP NOW

Are you a nurse who works with patients with breast cancer?
Then this is a program you can’t afford to miss.

Program Overview
Join us for an informative, interactive, evidence-based program on TYKERB^® (lapatinib), a treatment option for the treatment of advanced or metastatic HER2+ breast cancer. The program will discuss product information and adverse event management suggestions, patient education and teaching, and strategies for enhancing adherence to therapy.

RSVP Deadline:
Friday, May 9, 2008 – 5:00 PM ET

RSVP NOW

NO continuing nursing education (CNE) contact hours will be awarded. In order to register for this event you must acknowledge that this program does NOT offer continuing nursing education.

For more information please call 877-588-3343 (toll free) or 412-859-6108, or e-mail onsedge@ons.org.

This program is developed and funded by GlaxoSmithKline Oncology.

TYKERB is indicated in combination with capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline, a taxane, and trastuzumab.

Important Safety Information for TYKERB

TYKERB has been associated with hepatotoxicity. The hepatotoxicity may be severe and deaths have been reported. Causality is uncertain. Patients should receive liver function tests before initiation of treatment, every 4 to 6 weeks during treatment, and as clinically indicated. A dose reduction in patients with severe pre-existing hepatic impairment should be considered. Discontinue and do not restart TYKERB if patients experience severe changes in liver function tests.

As with other therapies for HER2 overexpression, TYKERB has been associated with reports of decreases in left ventricular ejection fraction (LVEF). Caution should be taken if TYKERB is to be administered to patients with pre-existing cardiac conditions, including uncontrolled or symptomatic angina, arrhythmias, or congestive heart failure. LVEF should be evaluated in all patients prior to and during treatment with TYKERB.

Diarrhea was the most common adverse event resulting in discontinuation of study medication. Proactive management of diarrhea with anti-diarrheal agents is important, and severe cases of diarrhea may require administration of oral or intravenous electrolytes and fluids and interruption or discontinuation of therapy with TYKERB.

TYKERB has been associated with interstitial lung disease and pneumonitis. Discontinue TYKERB if patients experience severe pulmonary symptoms.

TYKERB prolongs the QT interval in some patients. Consider ECG and electrolyte monitoring.

Fetal harm can occur when administered to a pregnant woman. Women should be advised not to become pregnant when taking TYKERB.

The most common adverse events (>20 percent) during treatment with TYKERB plus capecitabine were diarrhea, vomiting, nausea, fatigue, palmar-plantar erythrodysethesia, and rash.

Please see full prescribing information.